By Colin Kellaher

 

Johnson & Johnson on Tuesday said it is ending a study of an investigational HIV vaccine regimen after data showed the regimen didn't provide sufficient protection against HIV infection in young women in sub-Saharan Africa at high risk of acquiring HIV.

J&J was conducting the Phase 2b trial, known as the Imbokodo study, along with partners including the Bill & Melinda Gates Foundation and the National Institute for Allergy and Infectious Diseases, as part of its push to develop an HIV vaccine.

J&J said the investigational vaccine was found to have a favorable safety profile with no serious adverse events, and it noted that its HIV vaccine program continues with a global Phase 3 study dubbed Mosaico that is testing the safety and efficacy of a different composition of the HIV vaccine regimen among men who have sex with men and transgender individuals.

The Imbokodo proof-of-concept efficacy study began in 2017, reached full enrollment of about 2,600 young women in 2019 and completed vaccinations in June 2020.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

August 31, 2021 07:24 ET (11:24 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Grafico Azioni Johnson and Johnson (NYSE:JNJ)
Storico
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di Johnson and Johnson
Grafico Azioni Johnson and Johnson (NYSE:JNJ)
Storico
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di Johnson and Johnson